Avanos Medical, Inc.
AVNS
$12.71
-$0.39-2.98%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 689.20M | 687.80M | 681.50M | 682.40M | 680.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 689.20M | 687.80M | 681.50M | 682.40M | 680.10M |
| Cost of Revenue | 312.90M | 306.50M | 303.20M | 301.50M | 297.00M |
| Gross Profit | 376.30M | 381.30M | 378.30M | 380.90M | 383.10M |
| SG&A Expenses | 317.00M | 323.90M | 312.70M | 316.70M | 334.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.20M | 3.00M | 2.70M | 4.30M | 2.30M |
| Total Operating Expenses | 641.90M | 645.80M | 631.30M | 634.10M | 645.60M |
| Operating Income | 47.30M | 42.00M | 50.20M | 48.30M | 34.50M |
| Income Before Tax | -395.10M | -403.30M | 26.10M | 14.00M | 2.70M |
| Income Tax Expenses | -14.90M | -17.00M | 4.40M | 7.00M | 4.30M |
| Earnings from Continuing Operations | -380.20 | -386.30 | 21.70 | 7.00 | -1.60 |
| Earnings from Discontinued Operations | -4.40M | -5.80M | -6.00M | 700.00K | -60.60M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -384.60M | -392.10M | 15.70M | 7.70M | -62.20M |
| EBIT | 47.30M | 42.00M | 50.20M | 48.30M | 34.50M |
| EBITDA | 91.00M | 87.50M | 96.10M | 90.90M | 77.30M |
| EPS Basic | -8.36 | -8.52 | 0.34 | 0.17 | -1.33 |
| Normalized Basic EPS | 0.57 | 0.47 | 0.58 | 0.53 | 0.31 |
| EPS Diluted | -8.38 | -8.54 | 0.33 | 0.16 | -1.33 |
| Normalized Diluted EPS | 0.57 | 0.47 | 0.58 | 0.53 | 0.31 |
| Average Basic Shares Outstanding | 184.00M | 184.10M | 184.30M | 185.10M | 186.00M |
| Average Diluted Shares Outstanding | 185.70M | 185.60M | 186.20M | 186.40M | 186.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |